# 2026-22843: DEA Seeks Public Input on Next Year's Controlled-Drug Production Limits 2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-11-10, effective Establish the 2027 aggregate production quotas for controlled substances and assessment of annual needs for list I chemicals to be manufactured in the United States in 2027.; PRIA reads it as touching household money (as of 2026-11-11). - Canonical: https://policyrisk.com/federal-register/2026-22843 - As of: 2026-11-11 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2026-22843 - Title: Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027 - Type: Notice - Agencies: Justice Department; Drug Enforcement Administration - Citation: 91 FR 72566 - Published: 2026-11-10 - Effective: Establish the 2027 aggregate production quotas for controlled substances and assessment of annual needs for list I chemicals to be manufactured in the United States in 2027. - Comments close: not stated - Significant: no - Touches household money: yes - Regulation identifier numbers: none - Last updated: 2026-11-11 ## In one line DEA Seeks Public Input on Next Year's Controlled-Drug Production Limits ## Summary The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced. ## Abstract The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. ## Effects PRIA read - 2027 Production Limits Set for Controlled Substances: cost, medium. The DEA is proposing the 2027 aggregate production quotas (APQs) for Schedule I and II controlled substances and assessments of annual needs (AANs) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. These APQs/AANs set specific gram-based limits on how much of each listed… - Proposed Lower Quotas for Several Opioids: cost, medium. DEA proposes reduced 2027 APQs for several schedule II opioids — including fentanyl, hydrocodone (for sale), hydromorphone, oxycodone (for sale), and oxymorphone (for sale) — based on FDA's prediction that medical usage of schedule II opioids will decline an average of 9.68 percent from 2026 to 202… - Higher Quotas for ADHD Stimulant Medicines: benefit, medium. DEA proposes higher 2027 APQs for certain Schedule II stimulants used to treat ADHD — including d-amphetamine (for sale), d,l-amphetamine, lisdexamfetamine, and methylphenidate — to address projected increases in medical use and reported shortages. FDA predicted a 3.93 percent average increase in s… - Pentobarbital Increase to Build API Reserve: benefit, medium. DEA is proposing a higher 2027 APQ for pentobarbital than the 2026 established APQ to support Executive Order 14336 (Ensuring American Pharmaceutical Supply Chain Resilience) and to allow for a reserve stockpile of the active pharmaceutical ingredient for essential medications at the request of the… - More Quota for MDMA and Ibogaine Research: benefit, low. DEA proposes higher 2027 APQs for the Schedule I substances MDMA and ibogaine to support increased research and clinical trials related to potential treatments for conditions including post-traumatic stress disorder (PTSD) and depression. DEA links this increase to Executive Orders: E.O. 14379 (Add… - DEA's Diversion Estimates Will Reduce Quotas: benefit, medium. In compliance with 21 U.S.C. 826(i), DEA calculated national diversion estimates for five covered controlled substances and will consider these when setting 2027 APQs. The combined diversion estimates listed are: fentanyl 208 grams, hydrocodone 135,849 grams, hydromorphone 1,177 grams, oxycodone 40… ## Related documents - [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09 - [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20 - [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24 - [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19 - [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10 - [2026-22717](https://policyrisk.com/federal-register/2026-22717): Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance, 2026-11-06 ## Sources - [2026-22843 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/10/2026-22843/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of) - [2026-22843 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-10/pdf/2026-22843.pdf) ## Related - [Previous: 2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphet…](https://policyrisk.com/federal-register/2026-22842) - [Next: 2026-22844, National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice o…](https://policyrisk.com/federal-register/2026-22844) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2026-22843 (as of 2026-11-11).